Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686889 | 0.95 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL14898394 | 0.95 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL9114925 | 0.82 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL25908972 | 0.81 | KDM4E (0.33) | KDM4EMAPK1HIF1APAOXMAOA | |
| SCHEMBL24305739 | 0.81 | MEN1 (0.37) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20857570 | 0.80 | — | — | |
| SCHEMBL23707811 | 0.79 | KISS1R (0.38) | SMN1; SMN2KDM4EMAPK1HIF1AEPHX1 | |
| SCHEMBL9112258 | 0.77 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL16016693 | 0.75 | MEN1 (0.47) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL10078923 | 0.75 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | ALOX15 1148/4885MEN1 4140/4885CYP1A2 387/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ALOX15 1148/4885MEN1 4140/4885CYP1A2 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.